Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Paradigm Biopharmaceuticals Appoints Marco Polizzi As the New CEO

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a clinical-stage biopharmaceutical company focused on repurposing existing molecules for new indications with unmet clinical needs, appointed experienced pharmaceutical industry executive Marco Polizzi as its full-time Chief Executive Officer (CEO).

Marco Polizzi has over 30 years of experience in various commercially focused roles in the pharmaceutical industry, including creating new divisions within branded and generic pharmaceutical businesses. Marco Polizzi achieved outstanding sales results in these roles, forged several licenses, asset purchases, and other agreements with multiple top 10 global pharmaceutical companies and numerous other business partners, and generated significant returns for investors.

Marco Polizzi has a proven track record that is highlighted by several successful business and product launches in the U.S. These include a new Institutional (Hospital & Specialty Markets) business unit at Sandoz, driving the growth of a $900 million P&L, as well as directing commercial functions for a product launch (Bivalirudin) that achieved $100+ million in sales in its first year.

Paradigm has been seeking a CEO with the skills to fully unlock the company’s commercial value. Paradigm Chairman Paul Rennie said, “We expect Marco’s broad expertise will lead Paradigm to attain its strategic program objectives and increase shareholder value. Marco brings extensive U.S. pharmaceutical experience, a pharmaceutical industry network, operational excellence, transactional expertise, product launch, and product pricing and reimbursement experience to Paradigm.” We are confident that this experience will provide significant development and commercial value to Paradigm. Polizzi will be based in the United States and travel to Australia, Europe, and Asia as required.”

Polizzi commented, “With my pharmaceutical experience, I believe I will significantly contribute to the Paradigm business in the short and long term. I have had the opportunity to meet the Paradigm Board and key management personnel, and I can say that Paradigm’s business excites me. My feeling is primarily based on a potential blockbuster product, which may bring relief to the millions of people globally suffering from the pain and other debilitating effects of osteoarthritis and significantly increase shareholder returns. I look forward to meeting our shareholders in the coming months.”

The Paradigm Board thanks Dr. Donna Skerrett for her unwavering dedication and invaluable contribution to the company’s progress while serving as interim CEO. Dr. Skerrett will continue as Chief Medical Officer with a keen focus on completing the global phase 3 clinical programs for Zilosul® following the FDA’s fast-track designation protocol.


Other executives in the news can be found here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine